Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 39 shares, a drop of 91.8% from the July 30th total of 474 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
Basilea Pharmaceutica Stock Performance
Basilea Pharmaceutica stock opened at $77.40 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.68 and a current ratio of 5.11. Basilea Pharmaceutica has a one year low of $59.29 and a one year high of $77.40. The company has a 50-day simple moving average of $63.54 and a 200-day simple moving average of $66.94.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
